These preclinical lines of evidence highlight the possible synergy of combined targeting of CTLA-4 and PD-1, which has been demonstrated clinically in several solid tumors including melanoma [15, 16] and others [17, 18]. This evidence concerns the gene CTLA4 and melanoma.